The EHR4CR project is partially funded by the IMI Programme.
IP is necessary to fostering innovation, but in more recent years it has increasingly been recognised for the other benefits it provides.
EFPIA believes that interactions between the pharmaceutical industry and healthcare professionals have a profound and positive influence on the quality of patient treatment and the value of future research.
EFPIA and its member associations and companies have adopted codes and guidelines to ensure that interactions between the pharmaceutical industry and healthcare professionals interactions meet the high standards of integrity that patients, governments and other stakeholders expect.
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients